A Single Drug Dose Reversed Autism-Like Symptoms in Adult Mice Within Two Hours, UCLA Reports

A single dose of an existing drug reversed nearly every autism-like symptom researchers measured in adult mice within about two hours, according to work published Saturday in Nature Communications by a team at UCLA Health — a result that challenges the assumption that developmental brain changes are locked in for life.

The mice in the study were the offspring of mothers who experienced immune activation during pregnancy, a well-established laboratory model in which inflammation in the womb produces lasting neurological changes in the young. Those animals grow into adults with a recognizable cluster of traits: hyperexcitable brain circuits, heightened vulnerability to seizures, abnormal neuron firing, exaggerated sensitivity to sensory input and repetitive behavior.

The team, led by Dr. Harley Kornblum, director of UCLA's Intellectual and Developmental Disabilities Research Center, with Dr. Janel Le Belle as first author and Dr. Neil Harris as co-senior author, gave the adult animals one dose of rapamycin. The drug damps down the mTOR pathway, a signaling system that governs cell growth and protein production and that has turned up repeatedly in the genetics of autism and related conditions. Rapamycin is already approved in humans as an immunosuppressant for transplant patients.

Within roughly two hours, nearly all the measured symptoms improved. Brain overactivity dropped, seizure susceptibility fell, neuron firing patterns normalized, sensory hypersensitivity eased and repetitive behaviors declined. The speed is the striking part: two hours is far too fast to rebuild wiring or repair structural damage, which means the drug was changing how existing circuits operate rather than fixing how they were built.

"The adult brain may be more adaptable than we assumed, even when underlying structural changes from early development are still there," the researchers wrote. Their reading is that the developmental damage sets the brain into a persistently over-excitable state, and that state — not the damage itself — is what produces the symptoms. Shift the balance and the symptoms shift with it.

The limits are substantial and the authors flag them. The benefits were temporary, and repeated dosing stopped working after several weeks, suggesting the system adapts around the drug. These are mice, not people, and the maternal-inflammation model captures one route to autism-like traits among many; most autism in humans has no single identified cause. Rapamycin also carries real risks in long-term human use, including immune suppression and metabolic side effects. What the work offers is not a treatment but a target: if adult circuits remain this tunable, drugs aimed at that excitability balance become worth pursuing in ways the field had largely written off.